Ref | Underlying disease | Listed risk factors | Age y.o | Sex | Baseline sCr mg/dL | Max. sCr mg/dL | Abrupt sCr increase | MTX dose g/m2 | Max. MTX nmol/mL | Blood purification modalities | No. of times | HD QB | HD QD | HD h | DESA m2 | CPDG2 use |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
6 | ALL | NA | 44 | F | NA | NA | UK | 1.0 | 62 | HD | 1 | 400 | 500 | 4 | 1.8 | No |
6 | CLL | NA | 72 | M | NA | NA | UK | 1.0 | 1.5 | HD | 1 | 300 | 500 | 4 | 1.8 | No |
10 | DLBCL | NA | 36 | M | 0.8 | 3.2 | Yes | 3.5 | 31 | HD or HDF | 8 | 150 | NA | 4 | 1.5 | No |
10 | ALL | NA | 45 | M | 0.7 | 1.8 | Yes | 3.0 | 23 | ChH | 9 | – | – | – | – | No |
10 | ALL | NA | 16 | M | 0.5 | 3.8 | Yes | 5.0 | 134 | HD and ChH | 3 | 180 | NA | 4 | 1.3 | No |
11 | Histiocytoma | NA | 39 | NA | NA | 2.6 | UK | 12 | 688 | HD or HF | 3 | NA | NA | NA | NA | Yes |
11 | NHL | NA | 10 | NA | NA | 4.7 | UK | 5.0 | 9.2 | HD or HF | 8 | NA | NA | NA | NA | Yes |
12 | PCNSL | TAZ/PIPC | 58 | M | 0.7 | 3.1 | Yes | 2.5 | 93 | ChH | 4 | – | – | – | – | Yes |
12 | ALbL | Gemfibrozil | 39 | M | 0.7 | 6.0 | Yes | 3.0 | 41 | ChH | 4 | – | – | – | – | Yes |
13 | NHL | NA | 35 | M | 1.0 | 3.0 | Yes | 6.01 | 37 | PE or CHDF | 11 | – | – | – | – | No |
14 | PCNSL | NA | 68 | F | 0.8 | 5.2 | Yes | 3.0 | 22 | HD | 2 | NA | NA | NA | NA | Yes |
* | ALbL | Lansoprazole cefepime | 48 | M | 0.7 | 7.6 | Yes | 3.0 | 33 | PE and/or HD | 8 | 150 | 500 | 3 | 1.3 | No |
* | MPAL | Cefepime doripenem | 19 | M | 0.6 | 6.9 | Yes | 3.0 | 9.5 | PE or HD or ChH | 5 | 150 | 500 | 3 | 1.3 | No |
* | PCNSL | UTI | 72 | F | 0.5 | 2.0 | Yes | 2.0 | 7.7 | PE and/or HD | 7 | 150 | 500 | 3 | 1.1 | No |